首页> 外文期刊>Virchows Archiv >HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma
【24h】

HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma

机译:HER3过表达是肝外胆管癌的预后指标

获取原文
获取原文并翻译 | 示例
           

摘要

Members of the HER (ERBB) receptor protein tyrosine kinase family play an important role in regulating cellular division, proliferation, differentiation, and migration and have prognostic significance in a number of cancers. Here, we sought to define their role in extrahepatic cholangiocarcinoma (EHCC). HER2 and HER3 protein expression was studied in 230 EHCC cases using a tissue microarray and compared with clinicopathological variables, including the survival of EHCC patients. HER3 was predominantly localized to the cytoplasm, whereas HER2 exhibited a membranous expression pattern. Overexpression of HER2 and HER3 was observed in 6 % (13/224) and 39 % (90/230) of EHCCs, respectively. Membranous HER2 overexpression occurred more frequently in intraductal papillary neoplasms with an associated invasive carcinoma than in tubular adenocarcinomas (P = 0.02). HER3 protein was more commonly overexpressed in nodular and infiltrative than in papillary tumors (P = 0.03). HER3 overexpression was associated with decreased survival in both univariate (P = 0.01) and multivariate (P = 0.008) analyses, whereas HER2 overexpression was not associated with survival. HER2 and HER3 are overexpressed in subsets of EHCC patients. Notably, HER3 overexpression is correlated with decreased patient survival, suggesting that HER3 constitutes a prognostic factor as well as a potential candidate for targeted therapy.
机译:HER(ERBB)受体蛋白酪氨酸激酶家族成员在调节细胞分裂,增殖,分化和迁移中起重要作用,并在许多癌症中具有预后意义。在这里,我们试图确定它们在肝外胆管癌(EHCC)中的作用。使用组织芯片研究了230例EHCC患者的HER2和HER3蛋白表达,并与临床病理变量(包括EHCC患者的生存期)进行了比较。 HER3主要位于细胞质,而HER2表现出膜表达模式。分别在6%(13/224)和39%(90/230)的EHCC中观察到HER2和HER3的过表达。与伴有浸润性癌的导管内乳头状肿瘤相比,膜状HER2过度表达的发生率高于管状腺癌(P = 0.02)。结节性和浸润性中的HER3蛋白比乳头状肿瘤中更常见的过表达(P = 0.03)。在单变量(P = 0.01)和多变量(P = 0.008)分析中,HER3过表达与存活率降低相关,而HER2过表达与存活率无关。 HER2和HER3在EHCC患者子集中过表达。值得注意的是,HER3过表达与患者生存率降低相关,这表明HER3既是预后因素,也是靶向治疗的潜在候选者。

著录项

  • 来源
    《Virchows Archiv》 |2012年第5期|521-530|共10页
  • 作者单位

    Department of Pathology Asan Medical Center University of Ulsan College of Medicine 388-1 Pungnap-dong Songpa-gu Seoul 138-736 Korea;

    Applied Molecular Pathology Laboratory and Tissue Array Research Program Laboratory of Pathology National Cancer Institute National Institutes of Health Bethesda MD USA;

    Applied Molecular Pathology Laboratory and Tissue Array Research Program Laboratory of Pathology National Cancer Institute National Institutes of Health Bethesda MD USA;

    Department of Pathology Asan Medical Center University of Ulsan College of Medicine 388-1 Pungnap-dong Songpa-gu Seoul 138-736 Korea;

    Department of Pathology Asan Medical Center University of Ulsan College of Medicine 388-1 Pungnap-dong Songpa-gu Seoul 138-736 Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Extrahepatic; Bile duct; Cholangiocarcinoma; HER2; HER3; Immunohistochemistry; Prognosis;

    机译:肝外;胆管;胆管癌;HER2;HER3;免疫组化;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号